Molecular Biology and Immunopathology Core
The Molecular Biology and Immunopathology Core (MBIPC) and all 4 Center projects are located within the LSU SVM. MBIPC will be operationally headquartered within the existing administrative structure and laboratories of the Division of Biotechnology and Molecular Medicine (BioMMED). In addition, MBIPC will closely collaborate with the Center’s PCEC, also located within the SVM building. MBIPC will concentrate its support functions on molecular biology/recombinant DNA services and immunopathological characterization of in vitro and in vivo samples in conjunction with the SVM FACS Facility and the PBS Pathology Unit. Molecular biological services and reagents will include standard services such as DNA sequencing recombinant plasmid construction, cDNA library construction, and single cell DNA and RNA sequencing using the 10X genomics Chromium controller in conjunction with the Illumina Nextseq 550s/MiSeq sequencing equipment, for all 4 individual PJI’s projects. Advanced services will include processing and analysis of tissue/organ RNASeq experiments and single cell DNA and RNA sequencing data using advanced bioinformatics capabilities offered in conjunction with the Bioinformatics Unit of the LSU SVM LBRN/INBRE. In addition, MBIPC will offer real-time PCR analysis of mouse cytokines. The core has recently acquired the Agilent Seahorse XF platform which provides a direct measure of simultaneous measurements of OXPHOS and glycolytic rate, in live cells, in real-time. Using this technology, phenotypic evaluation of cancer cells in response to different metabolic substrates or inhibitors can be evaluated. Additional services include the production of monospecific and monoclonal antibodies, and coordination with the SVM Flow Cytometry Facility and the SVM Pathology Core offering advanced immunopathology and immunocytochemistry services. MBIPC has been established with strong experience in the application of advanced molecular and immunopathological expertise through coordinated access to existing SVM Facilities. New technological assays and methods will be adopted and/or developed over time based on individual project needs.